Marktanalyse - Toxoplasmosis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
39 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Toxoplasmosis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis — Pipeline Review, H2 2016, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.Toxoplasmosis.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Toxoplasmosis Overview 6

Therapeutics Development 7

Pipeline Products for Toxoplasmosis - Overview 7

Pipeline Products for Toxoplasmosis - Comparative Analysis 8

Toxoplasmosis - Therapeutics under Development by Companies 9

Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes 10

Toxoplasmosis - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Toxoplasmosis - Products under Development by Companies 13

Toxoplasmosis - Products under Investigation by Universities/Institutes 14

Toxoplasmosis - Companies Involved in Therapeutics Development 15

AbbVie Inc 15

Turing Pharmaceuticals AG 16

Toxoplasmosis - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Drug Profiles 25

CCP-010 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules for Toxoplasmosis - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules to Inhibit DHFR for Toxoplasmosis - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

toxoplasmosis vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

toxoplasmosis vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

toxoplasmosis vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

toxoplasmosis vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

TRP-004 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

TRP-012 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

TRP-013 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Toxoplasmosis - Dormant Projects 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39





List of Tables

Number of Products under Development for Toxoplasmosis, H2 2016 7

Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Toxoplasmosis - Pipeline by AbbVie Inc, H2 2016 15

Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Toxoplasmosis - Dormant Projects, H2 2016 37





List of Figures

Number of Products under Development for Toxoplasmosis, H2 2016 7

Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 23

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus